Sparks - Herantis Pharma

Herantis Pharma has completed a directed share issue, raising gross proceeds of €4.2m to support development of its potentially disease-modifying Parkinson’s disease (PD) therapy candidate HER-096. The company issued 2.41m new shares at €1.75 per share, representing a 15.7% discount to the recent volume-weighted average price. Proceeds will fund preparations for the planned Phase II study, partnership discussions and general corporate activities. Management views the financing as a timely and cost-efficient alternative to a rights issue, providing funding certainty amid volatile biotech markets. The new shares are expected to be listed shortly on Nasdaq First North Growth Market Finland.

The company reported positive Phase Ib data for HER-096 in October 2025 and recently presented biomarker data from the study, which supported HER-096’s mechanism of action as a potential disease-modifier for PD. The company plans to launch the Phase II trial in 2026.